Hidden within the full spectrum of physiologic signals emitted from the human body are data that can be used to pinpoint and distinguish disease. It is conventionally accepted that a large fraction of the total signal collected is considered devoid of biological information. We take all of the information, including the information considered uninformative and fully analyze and interpret it by leveraging the most advanced techniques in computer science and math. This results in a suite of mathematical features and machine-learned algorithms that when applied to billions of data points from the complete spectrum of physiologic signals, transforms them into precise, 3D images that distinguish healthy tissue/cells from diseased tissue/cells to better inform and support treatment decisions.
CHAOS BECOMES CLARITY
AgilyticsTM from A4L is a machine intelligence technology platform that analyzes phase space tomography data to identify and assess specific disease. It starts by mathematically deciphering critical patterns and relationships from billions of data points collected from thousands of patients. Powerful IBM cloud-based technology allows for analyses of these data-intense sets of physiologic signals. By applying a clinically-proven, machine-learned algorithm specific to a disease state, it identifies and characterizes the unseen relationships and turns them into precise, 3D images.
REDEFINE THE CARE PATHWAY
Advanced signal processing technology allows A4L to potentially impact existing care pathways in healthcare markets for the purposes of identifying and assessing disease. The initial focus of the A4L technology will be to transform the detection of coronary artery disease (CAD). What used to take days to weeks to reach a definitive answer can be replaced with a cost-effective, efficient, and safe way to pinpoint disease immediately.
ENVISIONED TO TRANSFORM CARE
Redefining the care pathway, and the benefits to patients, providers and insurers immediately becomes obvious. Suddenly, intensive testing that required massive imaging equipment and toxic contrasting agents is replaced with a handheld device and a 10-minute in-office procedure that is intended to deliver performance to at least the level of existing modalities.